Quantum Biopharma (NASDAQ:QNTM) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Quantum Biopharma (NASDAQ:QNTM) released its quarterly earnings data on Thursday. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.06), Zacks reports.

Quantum Biopharma Price Performance

Shares of NASDAQ QNTM opened at $3.23 on Friday. The stock has a market capitalization of $20.67 million, a price-to-earnings ratio of -0.39 and a beta of 0.45. Quantum Biopharma has a 12 month low of $2.07 and a 12 month high of $23.66. The firm’s 50 day simple moving average is $3.44 and its 200-day simple moving average is $4.05.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Quantum Biopharma stock. Virtu Financial LLC acquired a new position in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 10,406 shares of the company’s stock, valued at approximately $76,000. Virtu Financial LLC owned approximately 0.27% of Quantum Biopharma at the end of the most recent quarter. 1.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

QNTM has been the subject of several recent research reports. Wall Street Zen raised shares of Quantum Biopharma from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. Weiss Ratings lowered shares of Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.